Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes
作者机构：CEA-SaclayInstitut Frederic JoliotSIMOPROUniversitéParis-Saclay91191 Gif sur YvetteFrance Novartis Pharma AGBaselSwitzerland Present address:Integrated Biologix GmbHBaselSwitzerland
出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)
年 卷 期：2020年第17卷第6期
页 面：656-658页
核心收录：
学科分类：1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学]
基 金：The research leading to these results was supported by the lInnovative MedicinesInitiative Joint Undertaking ABIRISK project under grant agreement#115303 theresources of which comprise financial contribution from the European Union's Seventh Framework Programme(FP7/2007-2013) in-kind contributions from EFPIA companies This work was also supported by the Labex in Research on Medication and Therapeutic Innovation(LERMT)(to B.M.)and the CEA(to B.M.)
主 题：therapeutic antibodies clinical
摘 要：The clinical efficacy of therapeutic antibodies is recognized in many indications,explaining their rapid rise in the worldwide drug ***,therapeutic antibodies can be immunogenic by inducing a specific immune response characterized by the production of anti-drug antibodies(ADAs).ADAs can potentially increase the clearance of therapeutic antibodies,decrease their therapeutic effects1 and induce hypersensitivity *** humans are thought to be tolerant to their own proteins,sequences of the therapeutic antibodies have been humanized or human antibodies have been directly generated by technologies using human ***,human(ized)antibodies exhibit highly variable levels of immunogenicity,1,2 illustrating the poor understanding of the role of sequence humanization in mitigating the immunogenicity of therapeutic *** lines of evidence highlight the role of CD4 T lymphocytes during the initiation of an ADA response,3 but few T-cell epitopes of marketed therapeutic antibodies have been described to date.
维普期刊数据库